Garda Capital Partners’s Amgen AMGN Stock Holding History

Garda Capital Partners’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,968	Closed	-$517K	–	359
2022 Q4	$517K	Buy	+1,968	New	+$528K	0.03%	346

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Garda Capital Partners's AMGN Position: Q1 2023 in Review

Garda Capital Partners sold out of Amgen (AMGN) in Q1 2023, closing a stake of 1,968 shares — an estimated $517K sold.

Garda Capital Partners first reported a position in AMGN in Q4 2022 and held it in 1 quarter. The position peaked at $517K in Q4 2022. 2,435 funds tracked by Wall St. Rank hold AMGN as of Q1 2023.

Garda Capital Partners reported no remaining Amgen position as of Q1 2023 after selling out during the quarter.
Garda Capital Partners sold 1,968 Amgen shares in Q1 2023, an estimated $517K.
Garda Capital Partners first reported a position in Amgen in Q4 2022 and held it in 1 quarter.
Garda Capital Partners's Amgen position peaked at $517K in Q4 2022.
2,435 funds tracked by Wall St. Rank held Amgen as of Q1 2023.

Based on Garda Capital Partners's 13F filing for Q1 2023, filed 10 May 2023.